Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONGeneric

RENOVUE-65

IODAMIDE MEGLUMINE

Standard Dose
65%
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued
Summary

Approval overview RENOVUE-65 is listed in Drugs@FDA under application 017902 (NDA).

Marketing status: Discontinued Active ingredient IODAMIDE MEGLUMINE Form and strength INJECTABLE;INJECTION - 65% Sponsor BRACCO Submission history Latest submission status date: 2009-03-13 00:00:00.

Structured Monograph

Clinical summary

Approval overview RENOVUE-65 is listed in Drugs@FDA under application 017902 (NDA). Marketing status: Discontinued Active ingredient IODAMIDE MEGLUMINE Form and strength INJECTABLE;INJECTION - 65% Sponsor BRACCO Submission history Latest submission status date: 2009-03-13 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued

Interaction Notes

  • No interaction notes stored yet.